Clinical Trials

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT05926960 2026-03-09

PORTSIDE

38 enrolled

Melanoma, Skin Neoplasms

NCT05195632 2026-01-07

OCEANII

63 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06578559 2026-01-05

BRICKET

16 enrolled

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

Brain Neoplasms, Melanoma

NCT04061980 2025-11-19

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT04526782 2025-11-18

ENCO-BRAF

119 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04324112 2025-11-10

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Other hematologic neoplasm

45 enrolled

Leukemia, Hairy Cell

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

43 enrolled

Colorectal Neoplasms

NCT06887088 2025-10-01

ENCEFALO

33 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Melanoma

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT05706779 2025-09-02

NEORAF

30 enrolled

Colorectal Neoplasms

NCT03235245 2025-08-01

EBIN

271 enrolled

Melanoma

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Melanoma, Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

48 enrolled 24 charts

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT05004350 2025-04-15

NAUTICALCRC

107 enrolled

Colorectal Neoplasms

NCT06640166 2025-02-12

ECLYPse

25 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06411600 2024-11-08

BRAVE

94 enrolled

Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

5 enrolled 15 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

251 enrolled

Melanoma

NCT04074096 2024-06-03

BEPCOME-MB

10 enrolled

Brain Neoplasms, Melanoma

NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

6 enrolled 16 charts

Pancreatic Neoplasms

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

95 enrolled 30 charts

Colorectal Neoplasms

NCT02834364 2023-11-24

GMMG-BIRMA

12 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03563729 2023-07-13

MEMBRAINS

80 enrolled

Brain Neoplasms, Melanoma

NCT03911869 2023-05-31

POLARIS

13 enrolled 55 charts

Brain Neoplasms, Melanoma

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Colorectal Neoplasms

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

45 enrolled

Melanoma, Neoplasms

NCT01981187 2021-03-26

SIGNATURE

Other hematologic neoplasm

12 enrolled 13 charts

Hematologic Neoplasms

NCT02109653 2020-11-13

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn

Melanoma

NCT01820364 2017-01-09

LOGIC

15 enrolled 13 charts